ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs

On March 14, 2018 Mar. 14, 2018– ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting to be held from April 14-18, 2018 in Chicago (Press release, ImmunoGen, MAR 14, 2018, View Source [SID1234524769]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ImmunoGen has in-depth expertise in all aspects of ADCs, which has resulted in the most comprehensive toolbox of ADC technologies in the industry," said Richard Gregory, Ph.D., ImmunoGen’s chief scientific officer. "The data to be presented at AACR (Free AACR Whitepaper) further build on our leadership position in the space and demonstrate continued innovation, including further advancements to payloads and targets for anti-tumor activity, as well as insights into factors that determine the clinical efficacy of ADCs."

Details of ImmunoGen’s poster presentations are as follows:

Title: "A new class of DNA alkylating indolino-benzodiazepine agents (BIAs) linked with a DNA binding moiety for use with antibody-drug conjugates (ADCs)" (abstract #747)
Date:April 15, 2018
Time: 1:00 – 5:00pm CT

A new class of DNA alkylating effector molecules for use in ADC development in which an IGN (indolino-benzodiazepine) monomer subunit is connected to a DNA binding moiety (e.g., Bi-Aryl, or Bis-Aryl) are termed BIAs. BIA ADCs displayed potent, antigen-specific in vitro activity across a panel of FRα-expressing cell lines. In vivo, these ADCs demonstrated potent efficacy in xenograft models at doses well below the maximum tolerated dose.
Title: "Development of an in vivo model system to assess the interplay between the various drivers of antibody drug conjugate (ADC) activity" (abstract #753)
Date:April 15, 2018
Time: 1:00 – 5:00pm CT

To better understand the variables that impact ADC pharmacokinetics, tolerability, bio-distribution, and efficacy, a novel, cross-reactive model system was created. An anti-murine folate receptor alpha (FRα) antibody was generated that binds to both mouse and human FRα. The model system allows experiments to be designed in a cross-reactive system to examine how modifications to the antibody, linker or cytotoxic payload impact safety, and efficacy.
Title: "Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates" (abstract #2900)
Date:April 16, 2018
Time: 1:00 – 5:00pm CT

Endoglin/CD105 is a well-acknowledged endothelial cell proliferation marker, which is strongly expressed in tumor-associated vasculature. It was evaluated as an oncology target using ADCs of an anti-CD105 antibody with potent anti-microtubule maytansinoids DM1 and DM4, and the highly potent IGN DNA-alkylating payload, DGN549. Endoglin targeted huRH105-DM and huRH105-DGN549 conjugates produced modest anti-tumor activity and therapeutic indices in rat models.
Additional information and full abstracts can be found at www.aacr.org.

Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

On March 14, 2018 Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, reported financial results and a corporate update for the fourth quarter and full year ended December 31, 2017 (Press release, Immune Design, MAR 14, 2018, View Source [SID1234524768]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In 2017, we demonstrated the clinical activity of our two lead product candidates that turn "cold" tumors "hot," and enhanced our balance sheet," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design. "In 2018, our goal is to continue to create value and advance these novel therapies toward registration paths for patients with sarcoma and follicular lymphoma, while also setting the stage for potential expansion into multiple larger patient tumor populations."

2017 and Corporate Highlights

CMB305: novel prime-boost immunotherapy targeting NY-ESO-1+ cancers progressing to Phase 3 in synovial sarcoma patients

CMB305 monotherapy continues to show clinical benefit in soft tissue sarcoma (STS) patients

Highlights from the CMB305 monotherapy Phase 1 data presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2017 Annual Meeting (ASCO 2017) from 25 STS patients (including 14 with synovial sarcoma) include:

Over 90% of patients were metastatic, over 50% had received at least two lines of therapy, and over 50% of patients had disease progression at study entry.

Disease control rate (DCR) of 64% was observed, as well as durable tumor growth arrest in over 50% of the patients with disease progression at study entry.

As of the presentation, the median overall survival (mOS) had not yet been reached, with a median follow-up of 11.4 months.

In a combined set of 64 patients treated with either CMB305 or LV305 (the prime component of CMB305), there was an association between an immune response triggered by the therapy and better clinical outcome, particularly in patients with pre-existing anti-NY-ESO-1 immunity.

The safety profile was very favorable, with only one related Grade 3 adverse event.

Earlier this week, Immune Design announced updated data from this study.

With a median follow-up of 17.7 months, a mOS of 23.7 months has been reached for the whole population, but not yet for the synovial sarcoma patient subset.

Moreover, Immune Design continues to observe a favorable association between the CMB305-induced immune response and patient survival.

These data compare favorably to the reported mOS for approved second line agents, which are only 12.4-13.5 months for a diverse set of STS patients, and 11.7 months for synovial sarcoma patients specifically.

Immune Design reached agreement with the FDA for a pivotal Phase 3 trial design in synovial sarcoma patients.

The trial will compare CMB305 vs. placebo in NY-ESO-1+ synovial sarcoma patients in the maintenance setting after frontline chemotherapy. Progression free survival (PFS) and OS will be

independent primary endpoints, and if the PFS endpoint is successful, the FDA offered that it may support full approval. Immune Design expects the trial to start enrolling patients in mid-2018.

Median PFS (mPFS) is an endpoint specific to each particular line of metastatic sarcoma therapy. Immune Design believes that in the maintenance setting after frontline therapy in synovial sarcoma, there is an approximately 4-6 month relapse-free time period. Because CMB305 induced both an NY-ESO-1 immune response within the first 2-3 months and tumor-growth arrest in over half of the progressing patients in the earlier study, Immune Design believes that PFS, in addition to mOS, is a valid clinical endpoint in this maintenance setting.

CMB305 and atezolizumab combination showed strong anti-NYESO-1 immune response and improved clinical outcomes over atezolizumab alone in later-stage STS patients in an interim analysis presented at the European Society for Medical Oncology 2017 Congress (ESMO 2017).

88 patients (~44 in each arm) consisting of NYESO-1+ synovial sarcomas and mixoid round cell liposarcoma patients with recurrent disease. For the interim analysis, patients on the combination arm had worse characteristics than those on the atezolizumab-only arm (100% vs. 67% metastatic and 78% vs. 56% with at least two lines of chemotherapy).

DCR of 57% (including three partial responses (PRs) vs. 38% (no PRs)) was observed in the combination arm vs. the atezolizumab monotherapy arm in the full patient population.

Patients in the combination arm demonstrated stronger anti-NY-ESO-1 immune responses, including a significant difference in T cell response – 52% for the combination arm vs. 17% in the atezolizumab-only arm in the full patient population.

Immune Design estimates that there should be sufficient events to perform an OS analysis by approximately the end of 2018, when 72 events are expected to occur.

G100: a novel, synthetic TLR4 agonist for intratumoral immunotherapy is active with a preferable safety profile in patients with follicular lymphoma

In a dose escalation Phase 1 study, G100 monotherapy injected into a single lesion with low dose radiation (XRT) caused both treated and distal untreated tumors to become "hot" (including up-regulation of PD-1 and PD-L1), and caused local and systemic objective responses with a favorable safety profile in naïve and relapse/refractory indolent follicular lymphoma patients (presented at ASCO (Free ASCO Whitepaper) 2017)
.
In a randomized Phase 2 study, G100+XRT in combination with pembrolizumab produced robust objective responses in naïve and relapsed/refractory follicular lymphoma patients, superior to those observed with G100 + XRT.

With a median follow up of approximately 8 months, data from this 26-patient study presented at the 2017 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual meeting (ASH 2017) were:

A 15% objective response rate (ORR) consisting of PRs in those 13 patients who received G100+XRT vs. a 39% ORR (PRs) in the 13 patients who received the combination with pembrolizumab.

Higher tumor-infiltrating lymphocyte (TIL) numbers in distal, non- treated tumors were observed in patients treated with the combination, which also correlated with ORR.

Using TLR4 expression in the tumor as a possible predictive biomarker, patients with high TLR4 expression showed an increased ORR of 39% for those receiving G100+XRT and 57% for those receiving the combination.

Earlier this week, Immune Design announced updated data from this trial showing, now with a median follow-up of approximately 12 months, the ORR in the combination arm has increased from 39% to 54%, while the ORR of G100+XRT remains constant at 15%. In those patients with a high TLR4 expression in the tumor, the combination therapy ORR increased to 75%.

These data compare favorably to pembrolizumab monotherapy, which showed an 11% ORR in a separate recurrent/refractory FL study at ASH (Free ASH Whitepaper) 2017.

Immune Design is evaluating a potential registration path given the clinical responses observed in patients with recurrent/refractory disease and plans to solicit FDA feedback on the program in mid 2018.

Immune Design received Orphan Drug designation from the U.S. Food & Drug Administration and European Medicines Agency for G100 for the treatment of FL.

Completion of Follow-On Financing

In October 2017, Immune Design completed an underwritten follow-on public offering generating net proceeds of $86.6 million from both new and existing investors.

Expansion of Leadership Team

Expanded senior leadership team with additions of Melanie Morrison, Vice President, Oncology Platform Leader, and Heidi Petersen, Vice President of Regulatory Affairs.

Financial Results

Full Year 2017

Immune Design ended the fourth quarter of 2017 with $144.2 million in cash and cash equivalents, short-term investments, and other receivables compared to $110.4 million as of December 31, 2016. Net cash used in operations for the year ended December 31, 2017 was $53.1 million.

Net loss and net loss per share for the year ended December 31, 2017 were $51.9 million and $1.75, respectively, compared to $53.5 million and $2.47, respectively, for the same period in 2016.

Revenue for the year ended December 31, 2017 was $7.2 million and was primarily attributable to $6.9 million in collaboration revenue associated with the Sanofi G103 (HSV2 therapeutic vaccine) collaboration, and the remainder in product sales to other third parties. Revenue for the year ended December 31, 2016 was $13.3 million and was primarily attributable to $7.0 million in license revenue associated with Immune Design’s collaboration with Sanofi, $1.7 million in product sales to collaboration partner Sanofi and other third parties, and $4.6 million in collaboration revenue associated with the Sanofi G103 collaboration.

Research and development expenses for the year ended December 31, 2017 were $43.7 million, compared to $45.1 million for the same period in 2016. The $1.4 million decrease in research and development expense was primarily attributable to a decrease of $3.2 million in-licensing royalties and fees due to other third parties from which Immune Design licenses various technologies, and a $0.3 million decrease in clinical trial costs as a result of the timing of when the related costs associated with the company’s current clinical trials were incurred. Offsetting these decreases was a $1.2 million increase in personnel-related expenses, which was primarily due to an increase in compensation and benefits. In addition, there was a $0.7 million increase in facility related costs and expenses associated with the new facility lease for the company’s headquarters in Seattle, which commenced on January 1, 2017 and an increase of $0.3 million in contract manufacturing costs related to the various process development and manufacturing services.

General and administrative expenses for the year ended December 31, 2017 were $16.3 million, compared to $21.9 million for the same period in 2016. The $5.6 million decrease was primarily attributable to the settlement and license agreements with Theravectys in October 2016 involving the acquisition of certain present and future intellectual property rights from Theravectys and resolving the litigation initiated by Theravectys in July 2014 against Immune Design, as well as related claims and counterclaims.

Fourth Quarter

Net loss and net loss per share for the fourth quarter of 2017 were $12.0 million and $0.29, respectively, compared to $14.4 million and $0.57, respectively, for the fourth quarter of 2016.

Revenue for the fourth quarter of 2017 was $0.5 million, and was primarily attributable to collaboration revenue associated with the Sanofi G103 collaboration. Revenue for the fourth quarter of 2016 was $2.1 million and was primarily attributable to $1.6 million in collaboration revenue associated with the Sanofi G103 collaboration, and $0.5 million in product sales to collaboration partner Sanofi and other third parties.

Research and development expenses for the fourth quarter of 2017 were $8.5 million compared to $12.0 million for the same period in 2016. The $3.5 million decrease was primarily attributable to a $1.5 million decrease in clinical trial costs as a result of the timing of when the related costs associated with Immune Design’s current clinical trials were incurred, a $1.4 million decrease in in-licensing royalties and fees attributable to the settlement and license agreements with Theravectys in October 2016 involving the acquisition of certain present and future

intellectual property rights from Theravectys, and a $0.4 million decrease in contract manufacturing costs related to the timing of the various process development and manufacturing services during the comparable periods.

General and administrative expenses did not materially differ for the fourth quarter of 2017 compared to the same period in 2016. For the fourth quarter of 2017 general and administrative expenses were $4.3 million compared to $4.4 million for the same period in 2016.

Cash Guidance

Based on current expectations, Immune Design expects to have cash to fund operations into the second half of 2020.

Conference Call Information

Immune Design will host a conference call and live audio webcast this afternoon at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the fourth quarter and full year 2017 financial results and provide a corporate update.

The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the Immune Design website at View Source and will be archived there for 30 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code 3777048.

An archived copy of the webcast will be available on Immune Design’s website beginning approximately two hours after the conference call. Immune Design will maintain an archived replay of the webcast on its website for at least 30 days after the conference call.

GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018

On March 14, 2018 GlycoMimetics, Inc. (NASDAQ: GLYC) reported that preclinical research suggesting the potential of two of its drug candidates, GMI-1271 and GMI-1359, as treatments for acute myeloid leukemia (AML), metastasis in osteosarcoma and other cancers will be shared via poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018 in Chicago (Press release, GlycoMimetics, MAR 14, 2018, View Source [SID1234524767]). The company and its collaborators at the National Cancer Institute will highlight data from preclinical models of selected cancers in which GMI-1271, an antagonist of E-selectin, and GMI-1359, a dual antagonist of E-selectin and CXCR4, exhibited anti-cancer activity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key findings from the preclinical research include:

GMI-1271 could potentially be used with a hypomethylating agent, such as 5-azacitidine, to treat AML patients not healthy enough for intensive chemotherapy.
In preclinical models, GMI-1359 mobilized tumor-reactive T-cells from bone marrow, which could enhance effectiveness of treatments despite tumor resistance.
Both tumor growth and metastasis of osteosarcoma to lung tissue are reduced with GMI-1359 treatment.
"We are delighted to be able to share new data on potential expanded uses of our candidates GMI-1271 and GMI-1359 at the 2018 AACR (Free AACR Whitepaper) Annual Meeting," noted John Magnani, Ph.D., GlycoMimetics Senior Vice President and Chief Scientific Officer. "The new preclinical studies indicate a greater range of opportunities to potentially use our drug candidates to treat AML patients unable to withstand intensive chemotherapy, and also potentially to treat other cancers, such as osteosarcoma, that have resisted other therapies. In addition, the mechanism of action of our drug candidates may contribute to their use in immunotherapy. The AACR (Free AACR Whitepaper) data is also supportive, in particular, of the clinical trial we expect the Haemato Oncology Foundation for Adults in the Netherlands (HOVON) group to initiate, in which HOVON researchers will evaluate GMI-1271 in adults with newly diagnosed AML who cannot tolerate intensive chemotherapy, as well as in patients with myelodysplastic syndrome (MDS) with a high risk of leukemia."

Details of the AACR (Free AACR Whitepaper) presentations include:

Abstract #3514—Smith, T.A.G., et al. "Glycomimetic antagonist of E-selectin, GMI-1271, enhances therapeutic activity of the hypomethylating agent 5-azacitidine in the KG1 model of AML." Monday, April 16, 1:00-5:00 p.m. CT.

Abstract #5435—Fogler, W.B., et al. "Mobilization of tumor-primed, marrow infiltrating lymphocytes into peripheral blood with inhibitors of E-selectin or E-selectin and CXCR4." Monday, April 16, 8:00 a.m.-12:00 p.m. CT.

Abstract #6334—Ju, W., et al. "Dual E-selectin and CXCR4 inhibition reduces tumor growth and metastatic progression in an orthotopic model of osteosarcoma." Wednesday, April 18, 8:00 a.m.-12:00 p.m. CT.

The AACR (Free AACR Whitepaper) Annual Meeting 2018 takes place from April 14 to 18, at the McCormick Place North/South, Chicago. Meeting abstracts are available at AACR (Free AACR Whitepaper)’s website.

About GMI-1271

GMI-1271 is expected to enter Phase 3 clinical development in the third quarter of 2018. The molecule is designed to block E-selectin, an adhesion molecule on cells in the bone marrow, from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. In a completed Phase 1/2 clinical trial, the results of which were presented at the ASH (Free ASH Whitepaper) 2017 meeting , both newly diagnosed elderly and relapsed/refractory patients with acute myeloid leukemia (AML) treated with GMI-1271, together with standard chemotherapy, achieved better than expected remission rates and overall survival compared to historical controls, which have been derived from results from third-party clinical trials, as well as lower than expected induction-related mortality rates and incidence of severe mucositis. Treatment in these patient populations was generally well tolerated, with fewer than expected adverse effects.

About GMI-1359

GMI-1359 is currently in Phase 1 testing in healthy volunteers. GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. E-selectin and CXCR4 are both adhesion molecules that keep cancer cells in the bone marrow and affect cancer cell trafficking. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow such as AML and multiple myeloma or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer.

Aduro Biotech to Present at the 28th Annual Oppenheimer Healthcare Conference

On March 14, 2018 Aduro Biotech, Inc. (NASDAQ:ADRO) reported that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 28th Annual Oppenheimer Healthcare Conference in New York, NY on Wednesday, March 21, 2018, at 9:10 am Eastern Time (Press release, Aduro Biotech, MAR 14, 2018, View Source;p=RssLanding&cat=news&id=2338086 [SID1234524766]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro’s website at www.aduro.com.

Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual Meeting

On March 14, 2018 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, reported the company will present a poster at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting taking place April 14 – 18, 2018 in Chicago, Illinois (Press release, Alpine Immune Sciences, MAR 14, 2018, View Source [SID1234524752]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, entitled "CD80 vIgD-Fc proteins combine checkpoint antagonism and costimulatory signaling for potent antitumor immunity," will highlight preclinical data evaluating a novel immuno-oncology molecule derived from the company’s vIgD platform. An abstract of the presentation will be available on AACR (Free AACR Whitepaper) website after March 14, 2018.

Presentation details are as follows:

Session Category:
Clinical Research

Session Title:

Immune Checkpoints 4

Session Date and Time:
Tuesday, April 17, 2018 – 1:00 PM – 5:00 PM

Location:
McCormick Place South, Exhibit Hall A, Poster Section 25

Poster Board Number:
5

A copy of the poster will be made available on the Company’s website after it is presented.